LIMITED STOCK AVAILABLEPRICES SHOWN WHERE AVAILABLE
SEMAX

PERFORMANCE / SINGLE

SEMAX

5MG · 10MG
Important medical and research notice

This content is intended for educational and research reference only and does not constitute medical advice, diagnosis, or treatment. Experimental compounds are for research use only and are not for human consumption. Always consult qualified healthcare providers before starting any therapy.

Research Overview

A synthetic heptapeptide based on the ACTH(4-10) sequence, studied as an intranasal neurotrophic-signalling research compound.

Available Strengths

  • 5MG (XA5)
  • 10MG (XA10)

Research Protocol

Cited healthy-volunteer single-exposure dose range

PeriodDoseSprays (0.10 mL each)Volume
Single exposure (low)0.25 mg2.50.25 mL
Single exposure (high)1 mg101 mL

Reconstitution

Water volume5 mLConcentration1 mg/mLAdministrationIntranasal spray (metered actuator, 0.10 mL per spray)FrequencyPublished protocols vary substantially by study objective; no universal standard is specified in the cited literature.Cycle lengthNo universal standard cycle length; published studies range from single exposures to repeated 10-day courses in specific clinical contexts (see notes).

≈1.0 mg/mL (1,000 mcg/mL) once diluted to a 5 mL final volume in a metered nasal-spray actuator, delivering 100 mcg per 0.10 mL spray

  1. Add 3.0 mL of sterile 0.9% saline (or a compatible sterile nasal vehicle) to the 5 mg vial.
  2. Transfer to the actuator bottle and add further vehicle to reach a measured 5.0 mL final volume.
  3. Confirm the actuator delivers exactly 0.10 mL per full stroke; prime the pump per manufacturer instructions before use.

Research context

Reported to exert neurotrophic signalling effects on attention, memory and neurological outcomes without the hormonal effects of full-length ACTH.

Storage

Protected from light, refrigerated at ≤10°C, not frozen. Record preparation date, concentration, vehicle and storage conditions on the container; protect from light.

Research Notes

  • For educational and research reference only. Not medical advice and not intended for unsupervised human use.
  • This product is dosed as an intranasal spray, not injected. The spray-count column above reflects 0.10 mL metered actuations, not U-100 syringe units.
  • A separate post-stroke clinical research protocol cited 6,000 mcg/day for 10 days (repeated after a 20-day interval) — a substantially higher, clinically-supervised dose from a different research context than the single-exposure range above, not reflected in the schedule table.

References

Kaplan et al. (1996) — healthy-volunteer intranasal study↗Lebedeva et al. (2018) — fMRI neuroimaging results↗Gusev et al. (2018) — post-stroke recovery protocol↗

Source reference: PeptideDosages.com · 2026-08-18 · Exact strength match with the cited source

View in catalogueAll research protocols